Oramed Pharmaceuticals (ORMP) Competitors $2.21 +0.09 (+4.25%) Closing price 04:00 PM EasternExtended Trading$2.16 -0.05 (-2.26%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ORMP vs. FDMT, INBX, CADL, LRMR, RCKT, AMRN, ALDX, ALT, CTMX, and CGCShould you be buying Oramed Pharmaceuticals stock or one of its competitors? The main competitors of Oramed Pharmaceuticals include 4D Molecular Therapeutics (FDMT), Inhibrx Biosciences (INBX), Candel Therapeutics (CADL), Larimar Therapeutics (LRMR), Rocket Pharmaceuticals (RCKT), Amarin (AMRN), Aldeyra Therapeutics (ALDX), Altimmune (ALT), CytomX Therapeutics (CTMX), and Canopy Growth (CGC). These companies are all part of the "pharmaceutical products" industry. Oramed Pharmaceuticals vs. Its Competitors 4D Molecular Therapeutics Inhibrx Biosciences Candel Therapeutics Larimar Therapeutics Rocket Pharmaceuticals Amarin Aldeyra Therapeutics Altimmune CytomX Therapeutics Canopy Growth 4D Molecular Therapeutics (NASDAQ:FDMT) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment. Do insiders & institutionals hold more shares of FDMT or ORMP? 99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 9.6% of 4D Molecular Therapeutics shares are held by company insiders. Comparatively, 17.8% of Oramed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts recommend FDMT or ORMP? 4D Molecular Therapeutics presently has a consensus target price of $30.40, indicating a potential upside of 370.59%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe 4D Molecular Therapeutics is more favorable than Oramed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 4D Molecular Therapeutics 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.64Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is FDMT or ORMP more profitable? Oramed Pharmaceuticals has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -594,375.81%. Oramed Pharmaceuticals' return on equity of -19.37% beat 4D Molecular Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets 4D Molecular Therapeutics-594,375.81% -40.15% -36.43% Oramed Pharmaceuticals N/A -19.37%-18.28% Which has more risk & volatility, FDMT or ORMP? 4D Molecular Therapeutics has a beta of 2.83, suggesting that its share price is 183% more volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Does the media prefer FDMT or ORMP? In the previous week, 4D Molecular Therapeutics and 4D Molecular Therapeutics both had 2 articles in the media. Oramed Pharmaceuticals' average media sentiment score of 1.59 beat 4D Molecular Therapeutics' score of 0.62 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4D Molecular Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oramed Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has stronger earnings and valuation, FDMT or ORMP? Oramed Pharmaceuticals has higher revenue and earnings than 4D Molecular Therapeutics. Oramed Pharmaceuticals is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio4D Molecular Therapeutics$40K7,542.05-$160.87M-$3.53-1.83Oramed Pharmaceuticals$1.34M67.62-$19.06M-$0.35-6.31 SummaryOramed Pharmaceuticals beats 4D Molecular Therapeutics on 8 of the 15 factors compared between the two stocks. Get Oramed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORMP vs. The Competition Export to ExcelMetricOramed PharmaceuticalsMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$90.61M$10.61B$5.74B$9.78BDividend YieldN/A1.86%4.40%4.04%P/E Ratio-6.3121.2030.8326.39Price / Sales67.6231.79382.9086.63Price / CashN/A24.9137.7259.11Price / Book0.593.5110.106.62Net Income-$19.06M$210.11M$3.26B$265.42M7 Day Performance6.76%5.86%3.90%3.58%1 Month Performance2.31%11.12%3.73%0.46%1 Year Performance-7.53%-7.57%37.68%19.41% Oramed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORMPOramed Pharmaceuticals0.9912 of 5 stars$2.21+4.2%N/A-14.2%$90.61M$1.34M-6.3110Positive NewsFDMT4D Molecular Therapeutics2.2683 of 5 stars$7.27+0.1%$30.40+318.2%-58.8%$339.06M$40K-2.06120INBXInhibrx Biosciences1.3967 of 5 stars$23.87+2.3%N/A+86.1%$337.95M$200K-2.26166News CoverageCADLCandel Therapeutics2.5026 of 5 stars$5.96-2.1%$22.00+269.1%+1.7%$334.31M$120K-8.6460Positive NewsLRMRLarimar Therapeutics2.3892 of 5 stars$3.90-2.7%$18.43+372.5%-51.6%$331.94MN/A-2.5030Positive NewsRCKTRocket Pharmaceuticals4.8551 of 5 stars$3.03-0.7%$16.33+439.1%-82.7%$329.11MN/A-1.21240AMRNAmarin0.2907 of 5 stars$16.17+3.3%$12.00-25.8%+22.0%$324.07M$228.61M-4.41360Analyst DowngradeALDXAldeyra Therapeutics1.6828 of 5 stars$5.44+0.9%$9.50+74.6%+8.3%$322.84MN/A-6.4010ALTAltimmune3.3133 of 5 stars$3.56-1.9%$17.40+388.8%-49.9%$320.37M$20K-3.0250CTMXCytomX Therapeutics4.3657 of 5 stars$2.12+11.0%$5.75+171.2%+70.6%$314.98M$138.10M3.79170Positive NewsHigh Trading VolumeCGCCanopy Growth0.2734 of 5 stars$1.37+5.4%N/A-76.2%$311.80M$225.65M-0.453,150 Related Companies and Tools Related Companies 4D Molecular Therapeutics Competitors Inhibrx Biosciences Competitors Candel Therapeutics Competitors Larimar Therapeutics Competitors Rocket Pharmaceuticals Competitors Amarin Competitors Aldeyra Therapeutics Competitors Altimmune Competitors CytomX Therapeutics Competitors Canopy Growth Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORMP) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access